Estimating the case fatality ratio of the COVID-19 epidemic in China

Author:

Wang XingORCID,Ma ZihuiORCID,Ning YiORCID,Chen ChenORCID,Chen Rujin,Chen Qiwen,Zhang HengORCID,Li ChunmingORCID,He YanORCID,Wang Tao,Tong Cheng,Wu Junqing,Li Yuyan,Ma HandongORCID,Zhang ShaodianORCID,Zhao HongxinORCID

Abstract

AbstractBackgroundCorona Virus Disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China since late December 2019. Crude case fatality ratio (CFR) with dividing the number of known deaths by the number of confirmed cases does not represent the true CFR and might be off by orders of magnitude. We aim to provide a precise estimate of the CFR of COVID-19 using statistical models at the early stage of the epidemic.MethodsWe extracted data from the daily released epidemic report published by the National Health Commission P. R. China from 20 Jan 2020, to 1 March 2020. Competing risk model was used to obtain the cumulative hazards for death, cure, and cure-death hazard ratio. Then the CFR was estimated based on the slope of the last piece in joinpoint regression model, which reflected the most recent trend of the epidemic.ResultsAs of 1 March 2020, totally 80,369 cases were diagnosed as COVID-19 in China. The CFR of COVID-19 were estimated to be 70.9% (95% CI: 66.8%-75.6%) during Jan 20-Feb 2, 20.2% (18.6%-22.1%) during Feb 3-14, 6.9% (6.4%-7.4%) during Feb 15-23, 1.5% (1.4%-1.6%) during Feb 24-March 1 in Hubei province, and 20.3% (17.0%-25.3%) during Jan 20-28, 1.9% (1.8%-2.1%) during Jan 29-Feb 12, 0.9% (0.8%-1.1%) during Feb 13-18, 0.4% (0.4%-0.5%) during Feb 19-March 1 in other areas of China, respectively.ConclusionsBased on analyses of public data, we found that the CFR in Hubei was much higher than that of other regions in China, over 3 times in all estimation. The CFR would follow a downwards trend based on our estimation from recently released data. Nevertheless, at early stage of outbreak, CFR estimates should be viewed cautiously because of limited data source on true onset and recovery time.

Publisher

Cold Spring Harbor Laboratory

Reference21 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

3. A new coronavirus associated with human respiratory disease in China

4. News, I. SARS CoV-2 (formerly known as 2019-nCoV, or “Wuhan Coronavirus”) COVID-19 Outbreak. Access on February 11, 2020. Available from: https://www.isar-icar.com/Coronavirus.

5. WHO. Novel Coronavirus (2019-nCoV) SITUATION REPORT-5 25 JANUARY 2020. Access on January 25, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d_4.2020.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3